Company: MIRA
Filing Date: 2025-07-29
Form Type: PRER14A
Source: 0001641172-25-021434
Chunk: 214

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-07-29
Form: PRER14A
Chunk 214
---
CI involves cognitive decline, the symptoms are   
 not severe enough to qualify as dementia, including Alzheimer’s disease or other related 
 conditions.                                                                              |

Early identification and monitoring are key in managing MCI, especially to assess the potential risk of progression to more serious cognitive disorders.

Pharmaceutical Treatments of MCI

Currently, there is no FDA-approved medication specifically for Mild Cognitive Impairment (MCI). However, a few drugs are sometimes used off-label—especially when MCI is suspected to be an early stage of Alzheimer’s disease. Here’s a breakdown of medications that may be used for MCI, particularly in clinical or off-label contexts:

| Drug         
 Name         |     | Brand    
 Name     |     | Purpose                                                        |
| Donepezil    |     | Aricept  |     | Enhances                                                       
 acetylcholine to support memory and learning                   |
| Rivastigmine |     | Exelon   |     | Like                                                           
 donepezil; also approved for Parkinson’s dementia              |
| Galantamine  |     | Razadyne |     | Modulates                                                      
 nicotinic receptors as well as inhibiting acetylcholinesterase |

Emerging & Experimental Drugs (Under Investigation)

Anti-Amyloid Therapies for MCI and Mild Alzheimer’s Disease 5:

Lecanemab (brand name: Leqembi)is the first anti-amyloid therapy to demonstrate clear clinical benefit in individuals with Mild Cognitive Impairment (MCI) and mild Alzheimer’s disease. The drug, previously known as BAN2401, received accelerated approval from the U.S. Food and Drug Administration (FDA) on January 6, 2023, based on evidence from surrogate endpoints—specifically the reduction of beta-amyloid plaques—that are reasonably likely to predict clinical benefit.

5https://memory.georgetown.edu/news/lecanumab-leqembitm-fda-approved-for-individuals-with-mild-cognitive-impairment-mci-or-mild-dementia-due-to-alzheimers-disease-ad-collectively-called-early-ad-r-scott-turner/

| Moore Financial Consulting |

| MIRA Pharmaceuticals, Inc. | April 2025    |
| Valuation                  | Page 15 of 28 |

In contrast, aducanumab (brand name: Aduhelm™), another monoclonal antibody targeting beta-amyloid, was granted accelerated approval by the FDA in June 2021.